PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för AZD7762. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

29 hits

Bibliografisk träff 2024-05-27

Developing targeted therapies for neuroblastoma by dissecting the effects of metabolic reprogramming on tumor microenvironments and progression.

Jin W, Zhang Y, Zhao Z, Gao M.

Theranostics · research support, non-u.s. gov't; research-article; journal article · DOI 10.7150/thno.93962

Bibliografisk träff 2023-07-14

AZD7762 induces CRBN dependent BAG3 degradation through ubiquitin-proteasome pathway.

Liao Y, Yuan C, Huang M, Si W, Li D, Wu W, Zhang S, Wu R, Quan Y, Yu X, Liao S.

Anticancer Drugs · research support, non-u.s. gov't; research-article; journal article · DOI 10.1097/cad.0000000000001532

Bibliografisk träff 2023-03-16

Pan-Cancer analysis and experimental validation identify the oncogenic nature of ESPL1: Potential therapeutic target in colorectal cancer.

Zhong Y, Zheng C, Zhang W, Wu H, Wang M, Zhang Q, Feng H, Wang G.

Front Immunol · research support, non-u.s. gov't; research-article; journal article · DOI 10.3389/fimmu.2023.1138077

Bibliografisk träff 2022-11-18

Chk1/2 inhibitor AZD7762 blocks the growth of preantral follicles by inducing apoptosis, suppressing proliferation, and interfering with the cell cycle in granulosa cells.

Liu XM, Chen F, Zhang F, Zhao JZ.

Histol Histopathol · journal article · DOI 10.14670/hh-18-547

Bibliografisk träff 2022-08-16

Chk1/2 inhibitor AZD7762 enhances the susceptibility of IDH-mutant brain cancer cells to temozolomide.

Ozgiray E, Sogutlu F, Biray Avci C.

Med Oncol · journal article · DOI 10.1007/s12032-022-01769-x

Bibliografisk träff 2021-07-24

One therapeutic approach for triple-negative breast cancer: Checkpoint kinase 1 inhibitor AZD7762 combination with neoadjuvant carboplatin.

Zhu H, Rao Z, Yuan S, You J, Hong C, He Q, Yang B, Du C, Cao J.

Eur J Pharmacol · journal article · DOI 10.1016/j.ejphar.2021.174366

Bibliografisk träff 2020-10-23

Crystal Structure of the Kinase Domain of MerTK in Complex with AZD7762 Provides Clues for Structure-Based Drug Development.

Park TH, Bae SH, Bong SM, Ryu SE, Jang H, Lee BI.

Int J Mol Sci · research-article; journal article · DOI 10.3390/ijms21217878

Retracted publication 2020-09-01

Temozolomide and AZD7762 Induce Synergistic Cytotoxicity Effects on Human Glioma Cells.

Chen Y, Tseng BJ, Tsai YH, Tseng SH.

Anticancer Res · retracted publication; journal article · DOI 10.21873/anticanres.14517

Bibliografisk träff 2020-08-28

Radiosensitization of NSCLC cells to X-rays and carbon ions by the CHK1/CHK2 inhibitor AZD7762, Honokiol and Tunicamycin.

Liu B, Chen W, Li H, Li F, Jin X, Li Q.

Radiat Environ Biophys · research support, non-u.s. gov't; journal article · DOI 10.1007/s00411-020-00867-6

Bibliografisk träff 2019-07-27

Checkpoint kinase inhibitor AZD7762 enhance cisplatin-induced apoptosis in osteosarcoma cells.

Zhu J, Zou H, Yu W, Huang Y, Liu B, Li T, Liang C, Tao H.

Cancer Cell Int · research-article; journal article · DOI 10.1186/s12935-019-0896-9

Bibliografisk träff 2019-03-11

Discovery and Structural Characterization of ATP-Site Ligands for the Wild-Type and V617F Mutant JAK2 Pseudokinase Domain.

McNally R, Li Q, Li K, Dekker C, Vangrevelinghe E, Jones M, Chène P, Machauer R, Radimerski T, Eck MJ.

ACS Chem Biol · research support, non-u.s. gov't; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1021/acschembio.8b00722

Bibliografisk träff 2019-01-08

Acetyl-macrocalin B suppresses tumor growth in esophageal squamous cell carcinoma and exhibits synergistic anti-cancer effects with the Chk1/2 inhibitor AZD7762.

Wang JN, Che Y, Yuan ZY, Lu ZL, Li Y, Zhang ZR, Li N, Li RD, Wan J, Sun HD, Sun N, Puno PT, He J.

Toxicol Appl Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.taap.2019.01.005

Bibliografisk träff 2018-07-13

Effects of a checkpoint kinase inhibitor, AZD7762, on tumor suppression and bone remodeling.

Wang L, Wang Y, Chen A, Jalali A, Liu S, Guo Y, Na S, Nakshatri H, Li BY, Yokota H.

Int J Oncol · research-article; journal article · DOI 10.3892/ijo.2018.4481

Bibliografisk träff 2018-05-17

Repositioning of anti-cancer drug candidate, AZD7762, to an anti-allergic drug suppressing IgE-mediated mast cells and allergic responses via the inhibition of Lyn and Fyn.

Park YH, Kim DK, Kim HW, Kim HS, Lee D, Lee MB, Min KY, Koo J, Kim SJ, Kang C, Kim YM, Kim HS, Choi WS.

Biochem Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bcp.2018.05.012

Bibliografisk träff 2017-07-28

Gemcitabine and Chk1 Inhibitor AZD7762 Synergistically Suppress the Growth of Lkb1-Deficient Lung Adenocarcinoma.

Liu Y, Li Y, Wang X, Liu F, Gao P, Quinn MM, Li F, Merlino AA, Benes C, Liu Q, Gray NS, Wong KK.

Cancer Res · research-article; journal article · DOI 10.1158/0008-5472.can-17-0567

Bibliografisk träff 2017-01-03

Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine.

Isono M, Hoffmann MJ, Pinkerneil M, Sato A, Michaelis M, Cinatl J, Niegisch G, Schulz WA.

J Exp Clin Cancer Res · comparative study; research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/s13046-016-0473-1

Bibliografisk träff 2016-12-30

HPLC-UV method for simultaneous determination of MK-1775 and AZD-7762 in both acetonitrile-aqueous solution and mouse plasma.

Ebeid K, Ho GN, Salem AK.

J Chromatogr B Analyt Technol Biomed Life Sci · research-article; journal article · DOI 10.1016/j.jchromb.2016.12.031

Bibliografisk träff 2016-12-01

Suppression of the metastatic spread of breast cancer by DN10764 (AZD7762)-mediated inhibition of AXL signaling.

Park JS, Lee C, Kim HK, Kim D, Son JB, Ko E, Cho JH, Kim ND, Nan HY, Kim CY, Yoon S, Lee SH, Choi HG.

Oncotarget · research-article; journal article · DOI 10.18632/oncotarget.13088

Bibliografisk träff 2016-06-01

Birinapant (TL32711) Improves Responses to GEM/AZD7762 Combination Therapy in Triple-negative Breast Cancer Cell Lines.

Min DJ, He S, Green JE.

Anticancer Res · research-article; journal article

Bibliografisk träff 2016-02-04

Family-wide Structural Analysis of Human Numb-Associated Protein Kinases.

Sorrell FJ, Szklarz M, Abdul Azeez KR, Elkins JM, Knapp S.

Structure · research support, non-u.s. gov't; research-article; journal article · DOI 10.1016/j.str.2015.12.015

Bibliografisk träff 2014-01-22

Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors.

Sausville E, Lorusso P, Carducci M, Carter J, Quinn MF, Malburg L, Azad N, Cosgrove D, Knight R, Barker P, Zabludoff S, Agbo F, Oakes P, Senderowicz A.

Cancer Chemother Pharmacol · research support, non-u.s. gov't; research-article; multicenter study; clinical trial, phase i; journal article · DOI 10.1007/s00280-014-2380-5

Bibliografisk träff 2014-01-01

Checkpoint kinase inhibitor AZD7762 overcomes cisplatin resistance in clear cell carcinoma of the ovary.

Itamochi H, Nishimura M, Oumi N, Kato M, Oishi T, Shimada M, Sato S, Naniwa J, Sato S, Kudoh A, Kigawa J, Harada T.

Int J Gynecol Cancer · research support, non-u.s. gov't; journal article · DOI 10.1097/igc.0000000000000014

Bibliografisk träff 2013-07-28

Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours.

Seto T, Esaki T, Hirai F, Arita S, Nosaki K, Makiyama A, Kometani T, Fujimoto C, Hamatake M, Takeoka H, Agbo F, Shi X.

Cancer Chemother Pharmacol · comparative study; research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1007/s00280-013-2234-6

Bibliografisk träff 2012-07-20

The Chk1 inhibitor AZD7762 sensitises p53 mutant breast cancer cells to radiation in vitro and in vivo.

Ma Z, Yao G, Zhou B, Fan Y, Gao S, Feng X.

Mol Med Rep · journal article · DOI 10.3892/mmr.2012.999

Bibliografisk träff 2012-06-04

Discovery of checkpoint kinase inhibitor (S)-5-(3-fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by structure-based design and optimization of thiophenecarboxamide ureas.

Oza V, Ashwell S, Almeida L, Brassil P, Breed J, Deng C, Gero T, Grondine M, Horn C, Ioannidis S, Liu D, Lyne P, Newcombe N, Pass M, Read J, Ready S, Rowsell S, Su M, Toader D, Vasbinder M, Yu D, Yu Y, Xue Y, Zabludoff S, Janetka J.

J Med Chem · journal article · DOI 10.1021/jm300025r

Bibliografisk träff 2012-05-31

The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells.

Landau HJ, McNeely SC, Nair JS, Comenzo RL, Asai T, Friedman H, Jhanwar SC, Nimer SD, Schwartz GK.

Mol Cancer Ther · research support, non-u.s. gov't; journal article · DOI 10.1158/1535-7163.mct-11-0949

Bibliografisk träff 2011-12-21

Potentiation of the novel topoisomerase I inhibitor indenoisoquinoline LMP-400 by the cell checkpoint and Chk1-Chk2 inhibitor AZD7762.

Aris SM, Pommier Y.

Cancer Res · research support, n.i.h., intramural; research support, non-u.s. gov't; research-article; journal article · DOI 10.1158/0008-5472.can-11-2579

Bibliografisk träff 2010-03-16

In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762.

Mitchell JB, Choudhuri R, Fabre K, Sowers AL, Citrin D, Zabludoff SD, Cook JA.

Clin Cancer Res · research-article; journal article; research support, n.i.h., extramural · DOI 10.1158/1078-0432.ccr-09-3277

Bibliografisk träff 2008-09-01

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies.

Zabludoff SD, Deng C, Grondine MR, Sheehy AM, Ashwell S, Caleb BL, Green S, Haye HR, Horn CL, Janetka JW, Liu D, Mouchet E, Ready S, Rosenthal JL, Queva C, Schwartz GK, Taylor KJ, Tse AN, Walker GE, White AM.

Mol Cancer Ther · journal article · DOI 10.1158/1535-7163.mct-08-0492